Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAL-120 | Etoposide | Topo II | Chemotherapy | 0.47956 | -0.1663 | 0.3810 | 0.0949 | 1.2763 | 0.62593 | 0.99712 |
CAL-120 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.049579 | 0.1763 | 0.5193 | 0.0672 | 1.3302 | 0.036844 | 0.97412 |
CAL-120 | Trametinib | MEK | MAPK/nRTK | 0.046732 | 0.4153 | 0.2938 | 0.0276 | 1.2901 | 0.011053 | 0.98433 |
CAL-120 | Saracatinib | SRC | MAPK/nRTK | 15.6396 | 0.5261 | 0.1730 | 0.0078 | 0.3429 | 33.0327 | 0.96689 |
CAL-120 | ABT-737 | Bcl2/XL | Misc | 2.1471 | -0.4339 | 0.1998 | 0.1107 | 1.5326 | 3.968 | 0.99796 |
CAL-120 | Vorinostat | HDAC | Misc | 1.3545 | -0.2281 | 0.2409 | 0.0682 | 1.2739 | 2.1265 | 0.9951 |
CAL-120 | Luminespib | HSP90 | Misc | 0.0028134 | -0.1149 | 0.6933 | 0.1709 | 1.6073 | 0.0031386 | 0.99357 |
CAL-120 | A-1210477 | Mcl-1 | Misc | Inf | 0.9427 | 0.0152 | 0.0003 | 0.0000 | Inf | 0.34764 |
CAL-120 | Olaparib | PARP | Misc | 5.1241 | 0.2688 | 0.1427 | 0.0159 | 0.7347 | 22.8567 | 0.97745 |
CAL-120 | Bleomycin | Radiation | Misc | 1.687 | 0.0886 | 0.2320 | 0.0671 | 0.8116 | 2.7215 | 0.99732 |
CAL-120 | Ipatasertib | AKT | PI3K/mTOR | 58.682 | 0.5993 | 0.1297 | -0.0033 | 0.4437 | 5.6283 | 0.9635 |
CAL-120 | Alpelisib | PI3Ka | PI3K/mTOR | 21.5328 | 0.6075 | 0.0922 | -0.0015 | 0.5034 | 190.956 | 0.93579 |
CAL-120 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.5327 | 0.1514 | 0.2349 | 0.0129 | 0.4887 | 23.9822 | 0.95866 |
CAL-120 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0198 | -0.0168 | -0.0059 | 0.0000 | Inf | -0.45144 |
CAL-120 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.010544 | -0.0115 | 0.4872 | 0.0485 | 1.2658 | 0.010318 | 0.99716 |
CAL-120 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.5275 | 0.4163 | -0.0050 | 0.1797 | 1.1993e-05 | 0.81569 |
CAL-120 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.011487 | -0.0097 | 0.6018 | 0.0545 | 1.3448 | 0.011154 | 0.99759 |
CAL-120 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9240 | 0.0139 | -0.0025 | 0.0000 | Inf | 0.39826 |
CAL-120 | Buparlisib | pan PI3K | PI3K/mTOR | 0.70223 | -0.2717 | 0.3393 | 0.0962 | 0.9615 | 1.3908 | 0.99923 |
CAL-120 | Pictilisib | pan PI3K | PI3K/mTOR | 2.072 | 0.1944 | 0.2550 | 0.0144 | 0.4073 | 30.7541 | 0.99232 |
CAL-120 | Ceritinib | ALK | RTK | 0.79939 | -0.4322 | 0.3366 | 0.1170 | 1.0290 | 1.7983 | 0.99115 |
CAL-120 | Neratinib | EGFR/HER2 | RTK | 0.59003 | -0.2607 | 0.2238 | 0.0655 | 0.9310 | 1.9202 | 0.98923 |
CAL-120 | Tivantinib | MET | RTK | 0.25132 | -0.2562 | 0.4649 | 0.1572 | 1.1267 | 0.37355 | 0.99876 |
CAL-120 | Cediranib | VEGFR/cKIT | RTK | 1.037 | -0.1243 | 0.2989 | 0.0564 | 0.5757 | 6.9922 | 0.99099 |
CAL-120 | Cabozantinib | VEGFR2/MET | RTK | 7.3417 | 0.2574 | 0.0848 | 0.0071 | 1.8478 | 13.277 | 0.98262 |